Page 62, line 6 from the bottom, change "Organic" to --The organic--.

Page 69, line 14, change "Organic" to -- The organic -- .

Page 72, line 12, change "Aqueous" to -- The aqueous -- .

Page 74, last line, change "Organic" to -- The organic --.

Page 75, line 6, change "Organic" to -- The organic--.

Page 76, line 10, change "Organic" to -- The organic -- .

## IN THE CLAIMS:

Cancel, without prejudice to the subject matter involved, claims 1 28 inclusive and insert in their stead the following new claims:

--29. A compound of the formula

5 50 C 7 8

wherein R is 2-am nothiazol-4-yl the amino group of which is unprotected or protected with a protecting group,

NONN

R<sup>3</sup> is hydrogen, a pharmacologically acceptable salt forming group, a lower aralkyl group or a lower alkylene group,

 $R^5$  is hydrogen, methyl, vinyl, cyanovinyl, trifluoropropenyl, methoxymethyl, carbamoyloxymethyl, methylthiomethyl, cyanomethylthiomethyl, thiadiazolylthiomethyl, triazolylthiomethyl, aminomethylthiadiazolylthiomethyl, aminothiadiazolylthiomethyl, methoxy, fluoroethylthio, trifluoroethylthio, or halogen, and  $R^6$  is hydrogen a pharmacologically acceptable salt forming atom or group, a lower alkyl group, a lower alkenyl group or a lower aralkyl group.

A compound according to claim wherein R is hydrogen or a pharmacologically acceptable salt forming group,

R<sup>5</sup> is hydrogen, methyl, vinyl, trifluoropropenyl, methoxymethyl, carbamoyloxymethyl, methylthiomethyl, cyanomethylthiomethyl, thiadiazolylthiomethyl, methoxy, fluoroethylthio, trifluoroethylthio, or halogen, and

R<sup>6</sup> is hydrogen or a pharmacologically acceptable salt forming atom or group.

A. A compound according to claim 2, said compound being
7beta-[2-(2-aminothiazol-4-y1)-4-carboxy-2-butenoylamino]-35
cephem-4-carboxylic acid.

Theta-[2-(2-aminothiazol-4-yl)-4-carboxy-2-butenoylamino]-3 methyl-3-cephem-4-carboxylic acid.

- 5 -

2/Cont

- 75. A compound according to claim 26, said compound being 7beta-[2-(2-aminothiazol-4-yl)-4-carboxy-2-butenoylamino]-3-0 vinyl-3-cephem-4-carboxylic acid.
- 4. A compound according to claim , said compound being
  7beta-[2-(2-aminothiazol-4-yl)-4-carboxy-2-butenoylamino]-3
  trifluoropropenyl-3-cephem-4-carboxylic acid.
- 4. A compound according to claim 2, said compound being 7 beta-[2-(2-aminothiazol-4-yl)-4-carboxy-2-butenoylamino]-3 carbamoyloxymethyl-3-cephem-4-carboxylic acid.
- 36. A compound according to claim 36, said compound being 9 7beta-[2-(2-aminothiazol-4-yl)-4-carboxy-2-butenoylamino]-3=0 methoxymethyl-3-cephem-4-carboxylic acid.
- A compound according to claim 2, said compound being 7beta-[2-(2-aminothiazol-4-yl)-4-carboxy-2-butenoylamino]-3 methylthiomethyl-3-cephem-4-carboxylic acid.
  - A compound according to claim 26, said compound being
    7beta-[2-(2-aminothiazol-4-yl)-4-carboxy-2-butenoylamino]-32
    cyanomethylthiomethyl-3-cephem-4-carboxylic acid.
- 39. A compound according to claim 29, said compound being 7beta-[2-(2-aminothioazol-4-yl)-4-carboxy-2-butenoylamino]-3-triazolylthiomethyl-3-cephen-4-carboxylic acid.
- 40. A compound according to claim 29, said compound being 7beta-[2-(2-aminothiazol-4-yl) a-boxy-2-butenoylamino]-3-thiadiazolylthiomethyl-3-cephem-4-carboxylic acid.

- 6 -

BI Cont.

8

 $\mathcal{N}_{\bullet}$ 

A compound according to claim 2, said compound being 7beta-[2-(2-aminothiazol-4-yl)-4-carboxy-2-butenoylamino]-3-chloro-3-cephem-4-carboxylic acid.

46. A compound according to claim 26, said compound being 7beta-[2-(2-aminothiazol-4-yl)-4-carboxy-2-butenoylamino]-3-3

14. A compound according to claim 2, said compound being 7beta[2-(2-aminothiazol-4-yl)-4-carboxy-2-butenoylamino]-3+0 2-2-biffluoroethylthio-3-cephem-4-carboxylic acid.

45. An antibacterial composition which comprises an antibacterially effective amount of a compound of claim and a pharmaceutically acceptable carrier therefor.

A method for combatting bacteria which comprises bringing an antibacterially effective amount of a compound of claim 2 into contact with the bacteria.

## REMARKS

Further and favorable reconsideration is respectfully requested.

The specification has been reviewed for errors and certain editorial corrections are effected. It is believed that these

-7- / / 9

? Conest